Attached files

file filename
EX-10 - EXHIBIT 10.1 - VERITEQex10-1.htm
EX-10 - EXHIBIT 10.2 - VERITEQex10-2.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 30, 2014

 

 

VERITEQ CORPORATION
(Exact name of registrant as specified in its charter)

 

DELAWARE

 

000-26020

 

43-1641533

(State or other Jurisdiction of Incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

 

 

 

220 CONGRESS PARK DRIVE, SUITE 200
DELRAY BEACH, FLORIDA

 

33445

(Address of Principal Executive Offices)

 

(Zip Code)

 

 

 

Registrant’s telephone number, including area code: 561-846-7000

 

 

 

(Former name or former address if changed since last report.)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 
 

 

 

Item 1.01. Entry Into A Material Definitive Agreement.

 

Securities Purchase Agreement Effective December 26, 2014 and 8% Convertible Promissory Note due September 19, 2015

 

VeriTeQ Corporation (the “Company”) entered into a securities purchase agreement, dated December 17, 2014 but not entered into until December 26, 2014 (the “SPA”), with KBM Worldwide, Inc., an accredited investor (“KBM” or the “Lender”), pursuant to which the Company issued and sold to KBM a convertible promissory note, bearing interest at 8% per annum in the principal amount of $100,000 (the “Note”). In accordance with the terms of the SPA, the Company agreed to pay the Lenders expenses associated with the transaction in the amount of $4,000. As a result, the Company realized net proceeds from the sale of the Note in the amount of $96,000, which is to be used for general corporate purposes. The terms of the SPA also provide, for a period of six months following the effective date, a right of first refusal to KBM for certain future financings entered into by the Company for amounts less than $75,000.

 

The Note can be prepaid, at redemption premiums ranging from 10% to 35%, until 180 days following the issuance date of the Note, after which the Company has no right of repayment. The Note is convertible at a price per share equal to 61% of the average of the lowest three trading prices of the Companys common stock during the 10 trading days prior to conversion. If, at any time when the Note is outstanding, the Company issues or sells, or is deemed to have issued or sold, any shares of its common stock in connection with a subsequent placement for no consideration or for a consideration per share based on a variable price formula that is less than the conversion price in effect on the date of such issuance of shares of common stock, then the conversion price will be reduced to the amount of the consideration per share received for such issuance.

 

The Note contains certain covenants and restrictions including, among others, that for so long as the Note is outstanding the Company will not pay dividends or dispose of certain assets, and that the Company will maintain its listing on an over-the-counter market. Events of default under the note include, among others, failure to pay principal or interest on the note or comply with certain covenants under the note.

 

The foregoing descriptions of the SPA and the Note are summaries, and are qualified in their entirety by reference to such documents, which are attached hereto as Exhibit 10.1 and Exhibit 10.2, respectively, and are incorporated herein by reference.

 

Item 2.03. Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant.

 

The information set forth in Item 1.01 is incorporated herein by reference.

 

Special Note Regarding Forward-Looking Statements

 

This current report on Form 8-K contains"forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in VeriTeQ's Form 10-K, filed on April 15, 2014 and amended on August 19, 2014, and Form 10-Q filed on November 18, 2014, and future filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

  

 
 

 

 

Item 9.01. Financial Statements and Exhibits.

 

(d)

Exhibits

 

 

 

 

 

 

 

Exhibit

Number

 

Description

 

10.1

 

Securities Purchase Agreement dated December 17, 2014

       

 

10.2

 

Form of Convertible Promissory Note due September 19, 2015

  

 
 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

VeriTeQ Corporation 

 

 

 

Date: December 30, 2014 

 

/s/ Michael E. Krawitz 

     

 

 

Michael E. Krawitz

     

 

 

Chief Legal and Financial Officer 

 

 
 

 

 

Exhibit Index

 

Exhibit

Number

  Description

10.1

 

Securities Purchase Agreement dated December 17, 2014

     

10.2

 

Form of Convertible Promissory Note due September 19, 2015